Multiple Sclerosis
Conditions
Keywords
Specialty Pharmacy, Therapy Management, Medication Compliance, Medication Adherence, Medication Persistence, Health Outcomes
Brief summary
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
Interventions
DRUGGlatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
MS therapies (listed above) used according to prescribers' instructions.
Sponsors
Teva Neuroscience, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female, 18 years of age or older, with a diagnosis of MS. * Being treated with Glatiramer Acetate (GA) or (IFN)-β * Receiving therapy from a participating Specialty Pharmacy
Exclusion criteria
* Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study * Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP) * Unlikely to be able to participate for the full two years of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship of therapy Medication Possession Ratio (MPR), to patient outcomes | 12 months and 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Relationship of therapy adherence, defined as the accumulation of time from initiation to discontinuation of therapy and measured by time, to patient outcomes | 12 months and 24 months |
Countries
United States
Outcome results
None listed